Literature DB >> 24308581

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Kimberly M Thompson1, Radboud J Duintjer Tebbens.   

Abstract

Achieving the goal of a world free of poliomyelitis still requires significant effort. Although polio immunization represents a mature area, the polio endgame will require new tools and strategies, particularly as national and global health leaders coordinate the cessation of all three serotypes of oral poliovirus vaccine and increasingly adopt inactivated poliovirus vaccine (IPV). Poliovirus epidemiology and the global options for managing polioviruses continue to evolve, along with our understanding and appreciation of the resources needed and the risks that require management. Based on insights from modeling, we offer some perspective on the current status of plans and opportunities to achieve and maintain a world free of wild polioviruses and to successfully implement oral poliovirus vaccine cessation. IPV costs and potential wastage will represent an important consideration for national policy makers. Innovations may reduce future IPV costs, but the world urgently needs lower-cost IPV options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308581     DOI: 10.1586/14760584.2014.864563

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  24 in total

1.  Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Derek T Ehrhardt; Noha H Farag; Stephen C Hadler; Lee M Hampton; Maureen Martinez; Steve G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-01-03       Impact factor: 4.000

2.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

3.  Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Radboud J Duintjer Tebbens
Journal:  Vaccine       Date:  2015-02-18       Impact factor: 3.641

Review 4.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.

Authors:  Jean Guo; Sara Bolivar-Wagers; Nivedita Srinivas; Marisa Holubar; Yvonne Maldonado
Journal:  Vaccine       Date:  2015-01-16       Impact factor: 3.641

5.  Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-04-29       Impact factor: 4.000

6.  Poliovirus containment risks and their management.

Authors:  Radboud J Duintjer Tebbens; Dominika A Kalkowsa; Kimberly M Thompson
Journal:  Future Virol       Date:  2018-08-10       Impact factor: 1.831

7.  Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-01-20       Impact factor: 4.000

Review 8.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

9.  An economic analysis of poliovirus risk management policy options for 2013-2052.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

10.  Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  BMC Infect Dis       Date:  2015-09-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.